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Abstract
Background: Direct smear examination with Ziehl-Neelsen (ZN) staining for the diagnosis of pulmonary
tuberculosis (PTB) is cheap and easy to use, but its low sensitivity is a major drawback, particularly in HIV
seropositive patients. As such, new tools for laboratory diagnosis are urgently needed to improve the case
detection rate, especially in regions with a high prevalence of TB and HIV.
Objective: To evaluate the performance of two in house PCR (Polymerase Chain Reaction): PCR dot-blot
methodology (PCR dot-blot) and PCR agarose gel electrophoresis (PCR-AG) for the diagnosis of Pulmonary
Tuberculosis (PTB) in HIV seropositive and HIV seronegative patients.
Methods: A prospective study was conducted (from May 2003 to May 2004) in a TB/HIV reference hospital.
Sputum specimens from 277 PTB suspects were tested by Acid Fast Bacilli (AFB) smear, Culture and in house PCR
assays (PCR dot-blot and PCR-AG) and their performances evaluated. Positive cultures combined with the definition
of clinical pulmonary TB were employed as the gold standard.
Results: The overall prevalence of PTB was 46% (128/277); in HIV+, prevalence was 54.0% (40/74). The sensitivity
and specificity of PCR dot-blot were 74% (CI 95%; 66.1%-81.2%) and 85% (CI 95%; 78.8%-90.3%); and of PCR-AG
were 43% (CI 95%; 34.5%-51.6%) and 76% (CI 95%; 69.2%-82.8%), respectively. For HIV seropositive and HIV
seronegative samples, sensitivities of PCR dot-blot (72% vs 75%; p = 0.46) and PCR-AG (42% vs 43%; p = 0.54) were
similar. Among HIV seronegative patients and PTB suspects, ROC analysis presented the following values for the
AFB smear (0.837), Culture (0.926), PCR dot-blot (0.801) and PCR-AG (0.599). In HIV seropositive patients, these area
values were (0.713), (0.900), (0.789) and (0.595), respectively.
Conclusion: Results of this study demonstrate that the in house PCR dot blot may be an improvement for ruling
out PTB diagnosis in PTB suspects assisted at hospitals with a high prevalence of TB/HIV.
Background
Tuberculosis (TB) is a persistent health problem, being
responsible for 9.2 million cases per year. When asso-
ciated with human immunodeficiency virus (HIV), TB is
one of the leading infectious agents of death [1,2]. Fre-
quently, the diagnosis of TB is based on the positive
Acid Fast Bacilli (AFB) smear for Ziehl-Neelsen (ZN)
staining, and this method detects around 70% of cases
[2]. In clinical practice, the proportion of positive AFB
smears is around 40-60% [3]. Usually, HIV seropositive
patients demonstrate AFB smear negative staining for
Ziehl-Neelsen (ZN) and present lower yields in this test
for TB diagnosis. Moreover, these patients often present
more atypical radiological findings and a higher mortal-
ity rate. The usual laboratory procedure for clinical spe-
cimens involves microscopic examination for the
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presence of AFB and isolation and identification of the
organism by culture. In paucibacillary infections, the cur-
rent detection method is culture, which can take up to
six weeks until conclusion, due to the slow growth rate of
mycobacteria. Timely identification of mycobacterial
infection in HIV seropositive patients is critical to initiate
early specific treatment, to improve prognosis and to
reduce the risk of dissemination and spread to other hos-
pitalized patients [4]. Therefore, a global strategy for the
development and strengthening of laboratory diagnosis is
urgently needed to improve the case detection rate, espe-
cially in regions with high prevalence of TB and HIV.
In recent years, rapid diagnostic tests based on nucleic
acid amplification (NAA) tests have been developed
[5,6]. In industrialized nations, automated NAA com-
mercial tests are currently being used for the detection
of M. tuberculosis complex organisms in respiratory spe-
cimens from adult patients, HIV seronegative and non-
previously treated for TB [7].
Potential NAA techniques have been evaluated in
developing countries, as these methods are more afford-
able; these in house methods frequently use the IS6110
element [7-13]. Accordingly, we evaluated the perfor-
mance of two in house PCR methods: PCR dot-blot (col-
orimetric) and PCR-AG (non-colorimetric), using the
IS6110 element as a target, for the diagnosis of Pulmon-
ary Tuberculosis (PTB). We compared the status of HIV
and the history of anti-TB treatment, in a setting of high
prevalence of TB and HIV. This study was conducted
according to routine procedures at the Reference Hospi-
tal of TB/HIV of a Southern Brazilian city, Porto Alegre.
Methods
Study location and population
Porto Alegre, a southern Brazilian city, had a population
of 1,404,670, when the study was developed in 2004. Its
public health system includes eight community health
centers (CHC), 30 general hospitals, 10 specialized hos-
pitals for pulmonary disease diagnosis and treatment
and 3 hospitals based on correctional facilities. The
Parthenon Reference Hospital (PRH) is the largest TB/
HIV Reference Hospital and cares for both inpatients
and outpatients. In 2004, in Porto Alegre City, 1432
cases of TB were reported. Among them, 201 (20%)
were TB/HIV cases. These patients were assisted at
CHCs and 213 (51%) at public hospitals [14].
Design
A prospective study was conducted to evaluate the per-
formance of two molecular tests for PTB diagnosis.
Eligible and Ineligible Patients
PTB suspect patients, older than 18 years, assisted at
PRH from May 2003 to May 2004 were eligible. Eligible
patients were those: (1) who reported more than
3 weeks of cough. Patients ineligible were those receiving
anti-TB treatment when they were asked to participate in
the study. Patients with a history of previous TB were not
excluded. Patients were excluded from the study if any of
the following conditions were met: (1) culture was con-
taminated; (2) when expectorated sputum was not
obtained (3) laboratory or clinical data did not fulfill the
PTB definition; (4) written informed consent was not
obtained from the study participant. All clinical samples
were sent to the Laboratory of the State of RS, State
Foundation for Research in Health, Porto Alegre/RS/
Brazil, (FEEPS/Lacen/RS) for laboratory analysis. This
study was approved by the Institutional Review Boards of
FEPPS/RS (n. 01/2002).
Logistics
PTB was diagnosed using a sputum specimen and was
collected according to WHO recommendations [2]. The
selection of the TB suspects entering the diagnostic pro-
cess followed strictly routine diagnostic procedures of
the Hospital. The local site coordinator was responsible
for collecting all epidemiological data (patient interview
was conducted with a validated questionnaire) and all
specimens were sent to the Public State Laboratory, for
laboratory analysis. Pneumologists were blinded to PCR
results for the assessment of PTB cases, and laboratory
technicians were also blinded to the clinical TB status of
the clinical samples.
Clinical Methods
Clinical PTB was defined by pneumologists using the
clinical follow-up (symptoms, risk factors and chest X-
Ray). Assessment of PTB suspect was undertaken during
return visits by patients to the hospital and by the
review of medical records respectively 6 and 12 months
post diagnosis. Chest X-Ray was taken for those sus-
pects whose symptoms were compatible with active TB
and/or whose sputum smear AFB results were negative.
Identification of individuals who had had PTB in the
past was defined as when the patient, during interview,
related the previous use of anti-TB treatment for more
than 30 days. Non-treated PTB was defined as those
patients who were undergoing treatment for less than
14 days at the time of enrollment.
Routine laboratory process and performance evaluation
All clinical samples were sent to the Laboratory of the
State of RS, State Foundation for Research in Health,
Porto Alegre/RS/Brazil, for laboratory analysis. AFB
smear and culture assays were performed in the Culture
Laboratory and PCR assays were performed in the
Molecular Laboratory. All sputum samples were pro-
cessed by the acetylcysteine method. AFB smear
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staining, according to the Ziehl Neelsen method, and
culture were performed in Lowenstein Jensen method
and identified according to Kubica’s method [15].
PCR methods
The presence of the amplified fragment of the IS6110
insertion sequence in positive PCRs was checked by
electrophoresis with a 2% agarose gel, stained with ethi-
dium bromide, and visualized under ultraviolet light
[13]. The positive and negative controls were included
in the electrophoresis analysis.
The PCR colorimetric dot-blot assay was performed,
as previously published [13]. The DNA extraction from
sputum was performed as previously published [12].
DNA was amplified by in house PCR using the IS6110
element as target, utilizing biotinylated primers to
amplify a 132-bp DNA sequence specific to the M.
tuberculosis complex SK1 (5’-AACGGCTGATGAC-
CAAACTC-3’) and SK2 (5’-GGTTAGGTGCTGGT
GGTCC-3’) [13]. The primers were synthesized by Invi-
trogen (Molecular Biology Incorporating Life Technolo-
gies™and ResGen™Brand). PCR products were purified
in accordance with a description by Sperhacke et al
2004 and was analyzed in parallel using two procedures:
(1) electrophoresis on 2% agarose gel, using TBE (1 ×)
buffer, stained with ethidium bromide and visualized by
ultraviolet transilluminator and (2) transfer to a nylon
membrane and hybridization, according to Sperhacke
(2004).
Briefly, aliquots of the amplified products were
spotted. The amplified product was spotted on a nylon
membrane (Biodyne B Gibco-BRL) in holes of an
adapted support of propylene. A circle was drawn and
the specimens were spotted inside of this circle for
detection with a biotinylated DNA probe. The probe
used in hybridization was obtained by amplification with
the INS-1 primers (5’-CGTGAGGGCATCGAGGTGGC
-3’) and INS-2 (5’-GCGTAGGCGTCGGTGACAAA -3’).
The detection of hybridization was performed using a
conjugated streptavidin-alkaline phosphatase probe. The
positive reaction was obtained by adding BCIP and NBT
(; 5-bromo-4-chloro-3-indoyl phosphate and nitro blue
tetrazolium; Sigma®). The positive and negative controls
were included for each set of PCR A negative control
(PCR mixture with water instead of template DNA), and
positive control (M. tuberculosis Mt H37Rv, 100 ng)
were included for each set of PCR. To detect specimen
inhibitors, a duplicate tube of 50 μL PCR mix for each
specimen was spiked with 2 μL of an aqueous solution
containing 10 pg of purified DNA target [13]. All PCR
tests with discrepancies in results were tested in dupli-
cate. To avoid cross-contamination an extraction-nega-
tive control (a tube containing no organisms) and an
extraction-positive control (a dilution of M. tuberculosis
Mt H37Rv bacilli containing 50 colony forming units
[CFU]) were included for each set of extractions.
HIV
Blood samples were tested for HIV1 and HIV2 by serol-
ogy (GenScreen HIV Plus® BioRad), according to the
manufacturer’s instructions, and positive tests were con-
firmed by Western blotting (Genelabs® Diagnostics).
Ethics
This study was approved by the Institutional Review
Boards of FEEPS (n. 01/2002).
Gold Standard
Positive bacteriological result (at least one positive cul-
ture and biochemical identification) combined with
diagnosis of clinical PTB.
Independent Review
Two independent experts in TB diagnosis who did not
participate in the study reviewed clinical PTB. In the
absence of a consensus, a third TB expert was invited to
consider whether the patients with discordant results
would be considered to be free of TB or not.
Analysis
Epidemiological and laboratory data were stored in a com-
puter database and analyzed by appropriate statistical soft-
ware (SPSS 10®). The accuracy, sensitivity and spectivitiy
of both PCR methods was compared to the gold standard.
The negative predictive value (NPV) was calculated using
the following formula = SP test × (1-Prevalence)/(1-SE test)
× Prevalence+ SP test × (1-Prevalence). We used the TB
prevalence identified in the current study. The 95% confi-
dences Intervals were calculate using appropriate statistical
software (Epi info versão 6.04®). The area under the Recei-
ver operating characteristic (ROC) curve, known as the
AUC, was used to estimate the accuracy of diagnostic
tests. Using a dichotomous predictor, AUC will measure
the average of sensitivity and specificity.
Results
Study population
A total of 277 PTB suspect patients were enrolled. Pre-
valence of PTB was 46.2% (128/277); no history of prior
TB treatment was reported by 73.3% (203/277), and pre-
valence of HIV infection was 26.7% (74/277). The preva-
lence of PTB among HIV seropositive subjects was
54.0% (40/74). Some risk factors for PTB were signifi-
cantly more frequent in HIV seropositive patients than
HIV seronegative patients: alcohol addiction (44.0% vs
25.1%; p = 0.002); TB in the past (56.2% vs 23.1%, p =
0.0007), previous hospital admission (41.3% vs 25.6%, p =
0.01), and schooling of less than 8 years (72.0% vs 58.6%,
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p = 0.04) (Table 1). Weight loss was observed more fre-
quently among HIV seropositive individuals, 75.7%. The
most consistent predictor of PTB in all patients was sug-
gestive chest radiography (R: 0.36; p < 0.05), but in HIV
seropositive patients, this predictor was not significant
(R: 0.85; p = 0.32).
Chest X-Ray suggestive of classical tuberculosis
(upper-lobe fibrocavitary) was observed more frequently
in HIV seronegative (67.3%) than in HIV seropositive
individuals (32.2%) (data not shown).
Comparative performances of AFB smear, culture and two
in house PCR methods in patients with or without a prior
history of TB treatment, evaluated for PTB diagnosis
Overall, AFB smear sensitivity was 60% (CI 95%; 51,5%-
68.4%). PCR dot-blot sensitivity was [74% (CI 95%;
66.1%-81.2%)], which was significantly higher than that
of PCR-AG sensitivity [43% (CI 95%; 34.6%-51.7%)]. The
negative predictive value (NPV) of PCR dot-blot [81%
(CI 95%; 72.6% - 85.1%)] was similar to that of the NPV
of culture [88% (CI 95%; 82.0% - 91.9%)]; p = 0.067
(Table 2).
AFB smear and culture sensitivities were slightly
higher among those not previously treated by TB than
those observed among patients treated for TB in the
past (62% vs 47%; p = 0.16), (86% vs 68%; p = 0.06),
respectively. PCR dot blot specificity among those not
previously treated was similar to that observed in
patients treated for TB in the past (87% vs 84%; p =
0.42) and was slightly higher than PCR-AG specificity
for not previously treated TB (87% vs 71%; p = 0.36),
respectively (Table 2).
Among PTB suspects, AFB smear negative results
were found in 71.8% (199/277). Of these individuals, in
non-previously treated patients, PCR dot-blot had a
sensitivity of 68% (CI 95%: 52.9%-81.0%) (data not
shown).
Comparative performances of AFB smear, culture and two
in house PCR methods in patients evaluated for PTB
diagnosis, according to HIV status
The AFB smear sensitivity was significantly lower in the
HIV Seropositive group than in HIV seronegative indivi-
duals (43% for HIV seropositive and 68% for HIV sero-
negative; p < 0.05). In the HIV seronegative group, the
AFB smear sensitivity was higher among non-previously
treated patients than in those treated in the past, respec-
tively (70% and 54%; p < 0.05); in the HIV seropositive
group, there was no statistical difference among these
groups (Table 3).
As shown in Table 3, culture sensitivity and NPV
results remained similar (80% and 81% in HIV seroposi-
tive and, 85% and 90% in HIV seronegative groups, p =
0.31), in the two groups; PCR dot-blot sensitivity was
higher than PCR-AG for both HIV seropositive, (72%
and 42%, p < 0.05); and HIV seronegative (75% and
43%, p < 0.05) groups. NPV of PCR dot-blot was slightly
lower for HIV seropositive individuals (72%), in compar-
ison to HIV seronegative individuals (82%). Additionally,
NPV of the PCR dot-blot (72%) was similar to that
observed with culture (81%) in the HIV seropositive
group (p = 0.54).
In HIV seronegative patients, not previously treated
for TB, PCR dot-blot sensitivity was higher than that
observed for those treated in the past (74% vs 40%, p >
0.05); but was not observed in HIV Seropositive indivi-
duals (Data not shown).
In smear negative PTB suspects, according to HIV
status; PCR dot-blot had similar sensitivities (61% for
HIV Seropositive and 64% for HIV Seronegative, p =
Table 1 Patient symptoms and medical history, according to HIV status
HIV seronegative group HIV seropositive group
Symptoms and
Medical
History
Overall
suspects
N = 203
(%)
Non previously treated TB
suspects
N = 156
(%)
TB in the
past
N = 47
(%)
Overall
suspects
N = 74
(%)
Non previously
treated
TB suspects
N = 33
(%)
TB in the
past
N = 27
(%)
Positive
Culture
75
(36.9)
67
(42.9)
8
(17.0)
32
(43.2)
27
(81.8)
5
(18.5)
Weight lossa 104
(51.2)
79
(50.6)
25
(53.2)
56
(75.7)
36
(75.0)
20
(74.1)
Cough 190
(93.5)
148
(94.9)
25
(53.2)
67
(90.9)
43
(89.6)
24
(88.9)
Chest pain 121
(59.6)
96
(61.5)
31
(66.0)
42
(56.7)
22
(66.7)
14
(51.9)
Dyspnea 123
(60.1)
92
(58.9)
50
(67.6)
50
(67.6)
33
(100.0)
17
(63.0)
Comparison between HIV seropositive vs HIVseronegative ap = 0.004.
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Table 2 Comparative performance of AFB Smear, Culture and two in house PCR dot-blot methods in PTB suspects
Laboratory
Results and
Performance of methods
All Groupsa
N = 277
TB non-treated
Groupb
N = 203
TB in the past
Groupc
N = 74
TB
N = 128
Non-TB
N = 149
TB
N = 109
Non-TB
N = 94
TB
N = 19
Non-TB
N = 55
Performance of AFB smear Positive 77 1 68 0 9 1
Negative 51 148 41 94 10 54
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
60 99 99 74 62 100 100 70 47 98 90 84
CI 95(%) 51.5-68,4 96,7-99,9 93.8-99.9 67,9-80,0 53,0-71,1 96,8-100 95,7-100 61,5-76,9 26,1-69,4 91,3-99,9 59,6-99,5 73,9-91,8
Performance
of Culture
Positive 107 0 94 0 13 0
Negative 21 149 15 94 6 55
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
84 100 100 88 86 100 100 90 68 100 100 90
CI 95(%) 76,4-89,3 98,0-100 97,2-100 82,0-91,9 78,8-91,8 96,8-100 96,8-100 78,8-91,8 45,5-86,1 94,7-100 79,4-100 80,7-95,9
Performance
of PCR dot-blot
Positive 95 22 83 13 12 9
Negative 33 127 26 81 7 46
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
74 85 81 81 76 87 86 76 63 84 57 86
CI 95(%) 66,1-81,2 78,8-90,3 73,3-87,5 72,6-85,1 67,5-83,4 78,0-92,1 78,5-92,2 66,9-83,1 40,3-82,2 72,1-91,7 35,7-76,7 75,6-94,0
Performance
of PCR-AG
Positive 55 35 46 27 9 8
Negative 73 114 63 67 10 47
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
43 76 61 61 42 71 63 51 47 85 53 82
CI 95(%) 34,6-51,7 69,2-82,8 50,8-70,5 53,8-67,8 33,2-51,4 61,5-79,7 51,5-73,5 42,9-60,0 26,1-69,3 74,2-93 29,7-75,2 70,9-90,7
SE: Sensitivity, SP: Specificity, PPV: Positive Predictive Value, NPV: Negative Predictive Value.
aAll group.
bTB non-treated Group.
cTB in the past Group.
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0.12) and specificities (85% HIV Seropositive and 85%
HIV Seronegative, p = 0.10), respectively (Data not
shown).
Comparative estimate risk of correct diagnostic (odds
ratio-OR) using of AFB smear, culture and two in house
PCR methods
The risk of correct diagnostic (odds ratio-OR) was esti-
mated, in overall patients the OR were 3.8 (CI 95%;
3.0 - 4.9) to AFB smear, 8.1 to Culture (CI 95%;
5.4-12.0), 1.6 to PCR-AG (CI 95%; 1.2 - 1.9)] and 3.9 to
PCR dot-blot (CI 95%; 2.9 - 5.4)].
Among those not previously treated by TB the OR
were to 3.3 (CI 95%; 2.5 - 4.2) to AFB smear, 7.3 to
Culture (CI 95%; 4.5-11.6), 1.3 to PCR-AG (CI 95%; 1.0
- 1.7)] and 3.6 to PCR dot-blot (CI 95%; 2.5 - 5.0)].
However among HIV seropositive group the OR were
to 2.5 (CI 95%; 1.8 - 3.4) to AFB smear, 5.2 to Culture
(CI 95%; 2.8-9.8), 1.4 to PCR-AG (CI 95%; 0.97 - 2.2)]
and 3.1 to PCR dot-blot (CI 95%; 1.8 - 5.2)].
Inhibition and detection limit of two in house PCR
The inhibition of two in house PCR was 1.9%. Twenty-
three specimens presented less than 50 CFU in culture
(detection limit of in house PCR). These specimens were
included in the analysis. Among these cases: 7 (30%)
showed chest X-Rays suggestive of classical Tuberculo-
sis, 14 (61%) presented weight loss, 3 (13%) hepatitis, 23
Table 3 Comparative performance of AFB Smear, Culture and two in house PCR dot-blot methods stratifying by HIV
status
Laboratory
Results and
Performance of methods
HIV seronegative
Groupa
N = 203
HIV seropositive
Groupb
N = 74
TB
N = 88
Non-TB
N = 115
TB
N = 40
Non-TB
N = 34
Performance
of AFB smear
Positive 60 1 17 0
Negative 28 114 23 34
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
68 99 98 81 43 100 100 60
CI 95(%) 57,9-77,2 95,8-99,9 92,2-99,9 73,2-86,2 28,0-58,0 91,6-100 83,8-100 46,6-71,7
Performance
of Culture
Positive 75 0 32 0
Negative 13 115 8 34
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
85 100 100 90 80 100 100 81
CI 95(%) 76,3-91,5 97,4-100 96,1-100 83,7-94,2 65,5-90,3 91,6-100 91,0-100 67,0-90,7
Performance
of PCR dot-blot
Positive 66 17 29 5
Negative 22 98 11 29
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
75 85 79 82 72 85 85 72
CI 95(%) 65,2-83,2 77,1-90,9 69,8-87,2 74,0-87,8 57,2-84,6 70,4-94,4 70,4-94,4 57,2-84,6
Performance
of PCR-AG
Positive 38 27 17 8
Negative 50 88 23 26
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
43 76 58 64 42 76 68 53
CI 95(%) 33,1-53,7 68,1-83,6 46,2-69,9 55,5-71,5 28,0-58,1 60,2-88,4 48,1-83,8 39,1-66,6
SE: Sensitivity, SP:Specificity, PPV: Positive Predictive Value, NPV: Negative Predictive Value.
aHIV seronegative Group.
bHIV seropositive Group.
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(100%) cough, 14 (61%) chest pain and 15 (65%)
dyspnea.
Comparison of accuracy of AFB smear, Culture, PCR dot-
blot and PCR-AG tests using the area of ROC curve
Among the 203 HIV seronegative patients and PTB sus-
pects, ROC analysis showed the areas of AFB smear
(0.837), culture (0.926), PCR dot-blot (0.801) and PCR-
AG (0.599). Among the 74 HIV seropositive PTB sus-
pects, the ROC areas were (0.713), (0.900), (0.789) and
(0.595), respectively (Figure 1).
Discussion
This study compared the performance of bacteriological
and two in house PCR techniques for TB diagnosis in
PTB suspects that were assisted at a TB/HIV Reference
Hospital, using the first sample of expectorated sputum.
The aim of this study was to employ techniques in a
developing country with a large number of PTB sus-
pects, evaluated for HIV status and previous anti-TB
treatment. Patients were carefully characterized, with
independent reviews to determine the final PTB cases.
We observed a high prevalence of active PTB (46.2%),
and a high rate of HIV infection (27%) among PTB sus-
pects, confirming the epidemiological data described by
the Control Program of TB from Porto Alegre [14]. The
most consistent predictor of PTB in all patients was
suggestive of the chest X-Ray, but in HIV Seropositive
patients this was not significant, and these patients fre-
quently present more atypical radiological results [4].
Moreover, we observed a lower yield in the direct
microscopy examination of expectorated sputum, as
described previously [16,17]. These facts confirm that, in
developing countries with a high prevalence of TB and
HIV, better tests and more-efficient diagnostic processes
are urgently needed [16].
Sensitivities of the PCR dot-blot, shown in Table 2, ran-
ged from 63% to 76% and presented a trend towards
higher sensitivity than that obtained with PCR-AG (42%
compared to 47%). The PCR dot-blot sensitivities were
statistically higher among non-previously treated patients,
in comparison with those treated for TB in the past,
despite the HIV status. Nevertheless, similar results were
obtained with the AFB smear and culture, suggesting that
in the non-previously treated group there was a higher
bacterial load in the clinical specimens than in the group
of patients treated for TB in the past. Among smear nega-
tive PTB suspects with or without HIV, the sensitivity of
in house PCR (PCR dot-blot) ranged from 61% to 68%,
similar to that reported in the meta-analysis of Sarmiento
(32% to 92%), and also from studies carried out in devel-
oping nations using in house PCR techniques (40% to
64%), or using automated NAA tests (52% to 76%)
[3,16,18-23]. Specificities of in house PCR ranging from
76% for PCR-AG to 87% for PCR dot-blot were similar to
values described previously (77% to 92%) in developing
countries, using automated NAA tests, and lower (>95%)
than those described in industrialized countries [8,24-27].
Lower PCR-AG specificity (71%) among those patients
that had not previously been treated could be due to
contact with respiratory symptomatic patients; in fact
among these patients with false positive results, 18
(67%) reported previous tuberculosis contact. Lower
specificity of PCR dot-blot (84%) among those patients
with anti-TB treatment in the past was found to occur
in those patients with previous infection, thus it is not
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Figure 1 ROC space Plot accuracy estimates for each method and areas corresponding to 203 HIV seronegative and to 74 HIV
seropositive individuals. (Blue: AFB Smear; Green: Culture; Yellow: PCR-AG and Purple: PCR dot-blot).
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surprising that DNA could be detected from their
respiratory specimens. Decreased specificity for PCR has
also been reported in other studies using in house PCR
tests [28,29]
The lower sensitivity of both in house PCR and PCR-
AG (42%) among not previously treated patients and the
lower sensitivity of PCR dot-blot (63%) among patients
with previous anti-TB treatment may be due, in part, to
the presence of inhibitors that remain in the specimen
following the current extraction procedure and/or a
small number of mycobacteria that were unequally dis-
tributed in test suspension or below the detection limit
of the amplification of this test (50 CFU) [13]. In fact, in
our study, among false negative results, 20 (32%) in
PCR-AG and 3 (43%) patients in PCR dot-blot, were
below the detection limit of the amplification test. The
proportion of inhibitors was (1.9%) for in house PCR,
similar to the studies using automated NAA (0.85% to
5%) and lower than those of other reports that used in
house PCR (3.7% to 22.7%) [8,27,30,31]. The use of the
IS6110 insertion element as the PCR target could be a
potential source of decreased sensitivity, since MTB
lacks this element, as previously reported. However,
DNA fingerprinting studies performed in Brazil and
especially in our state (RS), did not detect the presence
of these strains. On the contrary, the great majority of
strains presented high copy numbers of IS6110 [32,33]
Conclusions
In this report, the sensitivity of the AFB smear was sig-
nificantly lower in HIV seropositive/TB patients, and
the sensitivity of both in house PCRs was not influenced
by the HIV status, similar to data reported by others
[16,17].
In the present study, the analysis of the plot in the
ROC space of accuracy in all patients shows a similar
performance for culture and PCR dot-blot in HIV Sero-
positive and HIV-PTB suspects. The culture method
showed the best performance for PTB diagnosis; how-
ever, more than 6 weeks are necessary to obtain the
final result. Fast identification of mycobacterial infec-
tions is necessary, especially in HIV/TB patients, who
need an early appropriate and specific treatment to
improve prognosis.
Possible study limitations of the study were the use of
only one respiratory specimen (which can lead to a lower
sensitivity) instead of two or three specimens for outpati-
ents, as proposed by WHO. However, we analyzed outpa-
tients and inpatients; rapid diagnosis of PTB is important
for these patients and it is sometimes difficult to obtain
three specimens, particularly in TB/HIV patients. Other
limitations were the presence of inhibitions of in house
PCR and the low limit of detection of 50 CFU. These find-
ings may influence the performance of PCR tests [3,7]. In
fact, laboratory studies have suggested low sensitivities of
PCR for the diagnosis of PTB and the significant variability
in sensitivities and specificities in different studies, mainly
due to the decontamination procedures, cross contamina-
tions, sampling error inhibitions, detection limit of tests
and quality of the reference standard [3,30,34].
Although the information in a diagnostic test can be
summarized using sensitivity and specificity, other para-
meters may be clinically important for the definition of
the accuracy of a laboratory test. The positive predictive
value (PPV) is the proportion of true positives in all
positive results and shows the probability that one
patient with a positive test has the disease. The negative
predictive value (NPV) is the proportion of true nega-
tives in all negative results and shows the probability
that one patient with a negative test does not have the
disease. However, these parameters are dependent of
prevalence rate. So for different prevalence rates can be
found different predictive values (NPV and PPV). The
predictive values showed in our setting with 46,2% of
TB prevalence, should be interpreted with attention and
prevalence of other settings should be considered.
The predictive values (PV) for different prevalence
rates could be calculate using specific formulas: PPV =
SEtest × Prevalence/(SE test X Prevalence) + (1-SP test) ×
(1-Prevalence) and NPV = SP test × (1-Prevalence)/(1-SE
test) × Prevalence+ SP test X (1-Prevalence)
Othe parameter utilized for the definition of teh accu-
racy of a laboratory tests is a ROC curve. ROC curve
analysis is a technique for assesing diagnostic tests,
based on the notions of specificity and sensivity, which
can be used to evaluate the accuracy of tests and also to
assess predictive models. We used this technique to
evaluate the accuracy of tests through of AUC.
The risk of correct diagnostic (OR) was higher than
Culture than others methods. However in patients HIV
seropositives the PCR dot-blot was similar to Culture,
confirming that this technique can be usefulness to cor-
rect diagnosis of PTB.
This study shows that in house PCR, using a colori-
metric system of revelation, may offer an improvement
for ruling out PTB diagnosis, for PTB suspects not trea-
ted previously, evaluated in hospitals, and in areas with
high prevalence of TB and HIV. Of the in house PCR
tests, PCR dot-blot seems to be more appropriate for
routine use, since this method includes a hybridization
step, which increases the sensitivity of detection. It also
offers higher accuracy, rapidity, ease of use, greater
safety, cost effectiveness and greater objectivity in the
reading of results, as reported previously [35].
Additionally, in house PCR tests are usually less costly
than automated NAA and might be introduced more
widely after a proper evaluation in different settings of
its clinical utility and cost-effectiveness.
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